MMV253

Zydus Cadila

Legend
Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA

  • Unknown 
Key features

  • Predicted 280-520mg human dose gives concentrations above Minimal Parasiticidal Concentration for >6 days

  • Low resistance potential from in vitro studies
Challenges

  • Synthesis and cost of goods
Status

  • First-in-Human study started in February 2019
Next milestone
  • Confirm human pharmacokinetics and efficacy
Previously

  • Name AZ13721412; from a discovery partnership between MMV and AstraZeneca, Bangalore
MMV Project Director

  • Illaria Di Resta